Epstein-barr virus (HHV-4) inoculation to rabbits by intranasal and oral routes results in subacute and/or persistent infection dissimilar to human disease

Intervirology

Volumn 57, Issue 5, 2014, Pages 254-269

  Rajčáni, Julius ^a   Szenthe, Kalman ^a   Ďurmanová, Vladimira ^a   Tóth, Agnes ^b   Ásványi, Balazs ^b   Pitlik, Ervin ^a   Stipkovits, Laszlo ^b   Szathmary, Susan ^b  

^a Research Triangle Europe Research Center   (Hungary)

^b Galenbio ^*  (Hungary)

Author keywords

Epstein Barr virus; Infection markers; Rabbit model

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; POLYPEPTIDE; PROTEIN P23; PROTEIN P54; VIRUS DNA; IMMUNOGLOBULIN G; VIRUS ANTIBODY; ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; LATENT MEMBRANE PROTEIN 1 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS INFECTION; GENE DOSAGE; IMMUNOBLOTTING; LYMPHOCYTOSIS; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; TRANSACTIVATION; VIRUS DETECTION; ANIMAL; BLOOD; DISEASE MODEL; EPSTEIN BARR VIRUS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; MONONUCLEAR CELL; MONONUCLEOSIS; PATHOLOGY; RABBIT; VIROLOGY; ANIMAL CELL; B LYMPHOCYTE; COMPARATIVE STUDY; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; INFECTION; INOCULATION; INTRANASAL INOCULATION; LEUKOCYTE; LIMIT OF QUANTITATION; ORAL INOCULATION; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; SUBACUTE INFECTION; VIRUS CAPSID; WESTERN BLOTTING;

ANIMALIA; HUMAN HERPESVIRUS 4; MIRIDAE; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; INFECTIOUS MONONUCLEOSIS; LEUKOCYTES, MONONUCLEAR; RABBITS;

EID: 84924180401     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000360223     Document Type: Article

References (40)

1. Hayashi K, Teramoto N, Akagi T: Animal in vivo models of EBV-Associated lymphoproliferative diseases: Special reference to rabbit models. Histol Histopathol 2002; 17: 1293-1310
2. Ferrari MG, Rivadeneira ED, Jarrett R, Stevceva L, Takemoto S, Markham P, Franchini G: HV(MNE) a novel lymphocryptovirus related to Epstein-Barr virus, induces lymphoma in New Zealand white rabbits. Blood 2001; 8: 2193-2199
3. Hayashi K, Chen HL, Yanai H, Koirala TR, Ohara N, Teramoto N, Oka T, Yoshino T, Takahashi K, Miyamoto K, Fujimoto K, Yoshikawa Y, Akagi T: Cyno-EBV (EBV-related herpesvirus from cynomolgus macaques) induces rabbit malignant lymphomas and their tumor cell lines frequently show specific chromosomal abnormalities. Lab Invest 1999; 79: 823-835
4. Hayashi K, Ohara N, Teramoto N, Onoda S, Chen HL, Oka T, Kondo E, Yoshino T, Takahashi K, Yates J, Akagi T: An animal model for human EBV-Associated hemophagic syndrome: Herpesvirus papio frequently induces fatal lymphoproliferative disorders with hemocytophagic syndrome in rabbits. Am J Pathol 2001; 158: 1533-1542
5. Hayashi K, Jin Z, Onoda S, Joko H, Teramoto N, Ohara N, Oda W, Tanaka T, Liu YX, Koirala TR, Oka T, Kondo E, Yoshino T, Takahashi K, Akagi T: Rabbit model for human EBV-Associated hemophagocytic syndrome: Sequential autopsy analysis and characterization of IL-2-dependent cell lines established from herpesvirus papio-induced fatal rabbit lymphoproliferative diseases with HPS. Am J Pathol 2003; 162: 1721-1736
6. Wutzler P, Meerbach A, Färber I, Wolf H, Scheibner K: Malignant lymphomas induced by an Epstein-Barr virus-related herpesvirus from Macaca arctoides - A rabbit model. Arch Virol 1995; 140: 1979-1995
7. Nash AA, Dutia BM, Stewart JP, Davison AJ: Natural history of murine gammaherpesvirus infection. Philos Trans R Soc Lond B Biol Sci 2001; 356: 569-579
8. Rajč́ni J, Kúelová'M: Murine herpesvirus pathogenesis: A model for the analysis of molecular mechanisms of human herpesvirus infections. Acta Microbiol Immunol 2005; 52: 41-71
9. Rajč́ni J, Kúelová'M: Murid herpesvirus 4 (MuHV-4): An animal model for human gammaherpesvirus research; in Minarovits J, Gonczol E, Valyi-Nagy T (eds): Latency Strategies of Herpesviruses. New York, Springer, 2006, chapt 5, pp 102-136
10. Stevenson PG, Simas JP, Efstathiou S, Immune control of mammalian gammaherpesviruses: Lessons from murid herpesvirus 4. J Gen Virol 2009; 90: 2317-2330
11. Cocco M, Bellan C, Tussiwand R, Corti D, Traggiai E, Lazzi S, Mannucci S, Bronz L, Palummo N, Ginanneschi C, Tosi P, Lanzavecchia A, Manz MG, Leoncini L: CD34 cord blood-transplanted Rag2-/- γ c -/- mice as a model for Epstein-Barr virus infection. Am J Pathol 2009; 173: 1369-1378
12. Castiglione F, Duca K, Jarrah A, Laubenbacher R, Hochberg D, Thorley-Lawson D: Simulating Epstein-Barr virus infection with CImmSim. Bioinformatics 2007; 23: 1371-1377
13. Takashima K, Ohashi M, Kitamura Y, Ando K, Nagashima K, Sugihara H, Okuno K, Sairenji T, Hayashi K: A new animal model for primary and persistent Epstein-Barr virus infection: Human EBV-infected rabbit characteristics determined using sequential imaging and pathological analysis. J Med Virol 2008; 80: 455-466
14. Okuno K, Takashima K, Kanai K, Ohashi M, Hyuga R, Sugihara H, Kuwamoto S, Kato M, Sano H, Sairenji T, Kanzaki S, Hayashi K: Epstein- Barr virus can infect rabbits by the intranasal and preoral route: An animal model for natural primary EBV infection in humans. J Med Virol 2010; 82: 977-986
15. Färber I, Hinderer W, Rothe M, Lang D, Sonneborn HH, Wutzler P: Serological diagnosis of Epstein-Barr virus infection by novel ELISAs based on recombinant capsid antigens p23 and p18. J Med Virol 2001; 63: 271-276
16. Microgen Line Assay: Determination of the avidity of anti-EBV-IgG against single antigens. Internal Notice Bauer 2003
17. Moss DJ, Burrows SR, Khanina R: EBV: Immunobiology and host response; in Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (eds): Human Herpesviruses, Biology, Therapy and Immunoprophylaxis. Cambridge, Cambridge University Press, 2007, pp 904-914
18. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Séguin C, Tuffnell PS, Barrell BG: DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984; 310: 207-211
19. De Paschale M, Cagnin D, Cerulli T, Manco MT, Agrappi C, Mirri P, Gatti A, Rescaldani C, Clerici P: Search for anti-EA D antibodies in subjects with an isolated VCA IgG pattern. Int J Microbiol 2010; 24:50-52
20. Ambinder R, Cesarman E: Clinical and pathological aspects of EBV and KSHV infect - ion; in Arvin A, Campadelli Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (eds): Human Herpesviruses, Biology, Therapy and Immunoprophylaxis. Cambridge, Cambridge University Press, 2007, pp 885-903
21. Klutts JS, Ford BA, Perez NR, Gronowski AM: Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J Clin Microbiol 2009; 47: 3204-3210
22. Bauer G: Simplicity through complexity: Immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology. Clin Lab 2001; 47: 223-230
23. De Paschale M, Clerici P: Serological diagnosis of EBV infection: Problems and solutions. World J Virol 2012; 11: 31-43
24. Schubert J, Zens W, Weissbrich W: Comparative evaluation of the use of immunoblots and of IgG avidity assays as confirmatory tests for the diagnosis of acute EBV infections. J Clin Virol 1998; 11: 161-172
25. Kenney SC: Reactivation and lytic replication of EBV; in Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (eds): Human Herpesviruses, Biology, Therapy and Immunoprophylaxis. Cambridge, Cambridge University Press, 2007, pp 403-443
26. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, Delecluse HJ: The Epstein-Barr virus lytic program is controlled by the cooperative functions of two transactivators. EMBO J 2000; 9: 3080-3089
27. Bhende PM, Seaman VT, Delecluse HJ, Kenney SC: The EBV lytic protein Z preferentially binds to and activates the methylated viral genome. Nat Genet 2004; 6: 1099-1014
28. Morrison TE, Mauser A, Wong A, Ting JP, Kenney SC: Inhibition of IFN-A signaling by an Epstein-Barr virus immediate early protein. Immunity 2001; 15: 787-799
29. Schillinger M, Kampmann M, Henninger K, Murray G, Hanseknabb I, Bauer G: Variability of humoral immune response in acute Epstein- Barr virus infection: Evaluation of the significance of serological markers. Med Microbiol Lett 1993; 2: 296-303
30. Leight ER, Sugden B: EBNA1: A protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol 2000; 10: 83-100
31. Westhoff-Smith D, Sugden B: Potential cellular functions of Epstein-Barr nuclear antigen 1 (EBNA1) of Epstein-Barr virus. Viruses 2013; 5: 226-240
32. Wu H, Cecarelli DF, Frappier L: The DNA segregation mechanism of Epstein-Barr virus nuclear antigen 1. EMBO 2000; 1: 140-144
33. Minarovits J: Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol 2006; 310: 61-80
34. Sivachandran N, Wang X, Frappier L: Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection. J Virol 2012; 86: 6146-6158
35. Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, Minarovits J: Epigenetic regulation of latent Epstein-Barr virus promoters. Biochem Biophys Acta 2010; 1799: 228-235
36. Sample J, Henson EB, Sample C: The Epstein- Barr virus nuclear protein-1 promoter active in type I latency is autoregulated. J Virol 1992; 66: 4654-4661
37. Kanai K, Takashima K, Okuno K, Kato K, Sano H, Kuwamoto S, Higaki H, Nagata K, Sugihara H, Kato M, Murakami I, Hayashi K: Lifelong persistent infection of rabbits with EBER-1-positive lymphocyte infiltration and mild sublethal hemophagocytosis. Virus Res 2010; 153: 172-178
38. Kalla M, Hammerschmidt W: Human B cells on their route to latent infection - early but transient expression of the lytic genes of Epstein- Barr virus. Eur J Cell Biol 2012; 91: 65-69
39. Young LS, Arrand JR, Murray PG: EBV gene expression and replication; in Arvin A, Campadelli- Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, (eds): Human Herpesviruses, Biology, Therapy and Immunoprophylaxis. Cambridge, Cambridge University Press, 2007, pp 461-489
40. Sano H, Nagata K, Kato K, Kanai K, Yamamoto K, Okuno K, Kuwamoto S, Higaki-Mori H, Sugihara H, Kato M, Murakami I, Kanzaki S, Hayashi K: EBNA-2 deleted Epstein- Barr virus from P3HR-1 can infect rabbits with lower efficiency than prototype Epstein- Barr virus genome B95-8. Intervirology 2013; 56: 114-121.